drugset / Trial / NCT07291635
Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
RandomizedParallel-groupDouble-blindPrevention
Summary
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
Timeline
- Start
- 2026-02-25
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Commercial Influenza vaccine | Vaccine | — | — |
| Subject | Recombinant Influenza vaccine candidate | Vaccine | 15 ug | — |
| Subject | Recombinant Influenza vaccine candidate | Vaccine | 30 ug | — |
| Subject | Recombinant Influenza vaccine candidate | Vaccine | 60 ug | — |